PsiOxus Therapeutics, Ltd. , a development stage biotechnology company, today announced the award of a US$3.3 million contract from the US Defense Threat Reduction Agency to develop biodefence vaccine adjuvants using the company's proprietary PolyMAP technology to help improve the safety and efficacy of two vaccines candidates: the recombinant ... (more)
http://www.laboratorynetwork.com/doc.mvc/dtra-psioxus-therapeutics-develop-biodefence-vaccine-adjuvants-0001?atc~c=771+s=773+r=001+l=a
http://www.laboratorynetwork.com/doc.mvc/dtra-psioxus-therapeutics-develop-biodefence-vaccine-adjuvants-0001?atc~c=771+s=773+r=001+l=a
No comments:
Post a Comment